Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stated in Gerald's blog big PR concerning Diagnostics due next week.
"On March 6-7, Amarantus Bioscience (“Amarantus” or the “Company”) made a joint presentation with Banyan Biomarkers (“Banyan”) at the 3rd Annual Traumatic Brain Injury Conference detailing the results of scientific research evaluating the therapeutic potential of the Company’s lead drug candidate MANF in Banyan’s cell culture testing system of apoptotic and necrotic cell death which mimcs traumatic brain injury. The abstract presented is attached hereto"
http://ih.advfn.com/p.php?pid=nmona&article=56634644
You must of sold. :( sad face
Before I invest in any company. I usually, sit down with CEO/Founder/President before making a rationalization. I do not rely on seeking beta. I met Gerald at the Crystal hotel in DC for the joint presentation with Banyan Biomarkers. I was also fortunate to talk with Mr. Hayes the founder of Banyan.
Lympro/Nuropro going to phase 2 and being commercialized this year will push .5 by summer. CLIA certification no FDA validation for diagnostics. On top of that, JV announcement, then Results on MANF.
AMBS will be above .2s by the end of the month JV/diagnostics
Float is locked did you see how shorts covered PPS spiked. Get ready fun is starting and will last all month just check out DEC's RUN
Are you sure, because it was only 3 days, and i could trade with teh CUSIP change just call your broker.
There are groups trying to squeeze the shorts. Speculation on diagnostics PR possible JV/ announcement. Complete DD is a must not like any other penny stock.
L2 THIN LEAVING ABOVE .084S
BREAKOUT
Serious capital is flowing through 29million market cap.
Exactly, NoC the run will be much larger due to PR/JV announcement. National recognition is what AMBS is about to receive through their "game-changer" Lympro/Nuropro diagnostics.
Wow, 200,000 block printed!
AMBS leaving MRs missing the boat again
.08s are right around the corner.
Folks .08s will be here alot faster, then you think
Here is the link for the $4,500 2012 research report Amarantus is mentioned and has a nice piece. http://www.neurotechindustry.org/home.html
Thanks Lew for another DD DOC on Diagnostics. Wow commercialization this year! Phase 2 could be announced next week. https://docs.google.com/document/d/1ihv24O8iUYILQocEtGTicKO7UJtaMQiUmUr_5hEbFL0/edit?pli=1
The CEOs game plan is the same as last push, but this time very big diagnostics/JV news coming this month. Huge speculative run will start next week with the PR pipeline locked and loaded.
Did you forget to reload when the bottom was in?
Folks, Gerald's game plan is the same as the last run. This time huge diagnostic PR next week, which is stated in the last few PRs. Gerald still has the CUSIP weapon, which will propel AMBS back over 52 week high. Get ready the push is coming.
PPS holds over 50MA. Huge moving average bullish confirmation
MODS please sticky #67911. Thanks lew.
No, shares a fine until another 8k is released. The precedent filing:
Item 8.01. Other Events
On 27 November 2012, Amarantus Biosciences, Inc. changed its name to Amarantus Bioscience, Inc. This was reported on a previously timely filed 8-K. On 2 January Amarantus received notice that DTCC will process the change in name to Amarantus Bioscience, Inc. on 3 January 2013.
A copy of the email from Andrea Hedgeman,?Mandatory Reorganization,?DTCC, stating 3 January 2013 as the date of processing for the change in name to Amarantus Bioscience, Inc. is attached as Exhibit 99.1 to this Report.
Item 9.01 Financial Statements and Exhibits
AMBS-"The Company will also evaluate the acquisition/in-licensure of clinical-stage drug candidate to complement MANF within the Amarantus Therapeutics subsidiary, and may evaluate additional strategic significantly undervalued opportunities over time using its deep industry knowledge and connections"
http://ir.stockpr.com/amarantus/company-news/detail/644/amarantus-bioscience-modifies-business-structure-to-support-product-development-strategy
"The Company will also evaluate the acquisition/in-licensure of clinical-stage drug candidate to complement MANF within the Amarantus Therapeutics subsidiary, and may evaluate additional strategic significantly undervalued opportunities over time using its deep industry knowledge and connection"
source: http://ir.stockpr.com/amarantus/company-news/detail/644/amarantus-bioscience-modifies-business-structure-to-support-product-development-strategy
PPS will be over 50ma tomorrow. Afterhours PR big catalyst in conjunction for diagnostic speculation next week. Also, CUSIP change is another. Ducks are lining up just like the .194 run a few months back on minimal PR. Fast forward and the progression is at an exponential rate.
Austin, TX - April 2, 2013 - Applied Nanotech Holdings, Inc. (OTC BB: APNT) announced that its subsidiary, Applied Nanotech, Inc., will be presenting its latest advancements in inks and pastes for printed electronic applications at the prestigious 10th International Conference and Trade Show on printed electronics organized by IDTechEx in Berlin, Germany April 17-18, 2013. More information on the show can be obtained at www.idtechex.com/printed-electronics-europe/pe.asp